Author

Geert R. D'Haens

ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE AND -EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE AND -EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Geert R. D'Haens  et al.

IMPACT OF PRIOR BIOLOGIC/JANUS KINASE INHIBITOR THERAPY ON THE EFFICACY OF ETRASIMOD: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
IMPACT OF PRIOR BIOLOGIC/JANUS KINASE INHIBITOR THERAPY ON THE EFFICACY OF ETRASIMOD: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Geert R. D'Haens  et al.

EFFICACY AND SAFETY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A RANDOMIZED PHASE 3 U-EXCEL STUDY
EFFICACY AND SAFETY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A RANDOMIZED PHASE 3 U-EXCEL STUDY

Geert R. D'Haens  et al.

BASELINE HYPERTROPHY OF THE SUBMUCOSA AT INTESTINAL ULTRASOUND PREDICTS FAILURE OF TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS
BASELINE HYPERTROPHY OF THE SUBMUCOSA AT INTESTINAL ULTRASOUND PREDICTS FAILURE OF TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS

Geert R. D'Haens  et al.

RADIOLOGIC EVALUATION OF FILGOTINIB TREATMENT IN PERIANAL FISTULIZING CROHN’S DISEASE USING A NOVEL SCORING SYSTEM
RADIOLOGIC EVALUATION OF FILGOTINIB TREATMENT IN PERIANAL FISTULIZING CROHN’S DISEASE USING A NOVEL SCORING SYSTEM

Geert R. D'Haens  et al.

THE EFFECT OF APPENDECTOMY ON THE CLINICAL COURSE OF ULCERATIVE COLITIS (ACCURE): PRELIMINARY RESULTS OF AN INTERNATIONAL, RANDOMIZED, CLINICAL TRIAL
THE EFFECT OF APPENDECTOMY ON THE CLINICAL COURSE OF ULCERATIVE COLITIS (ACCURE): PRELIMINARY RESULTS OF AN INTERNATIONAL, RANDOMIZED, CLINICAL TRIAL

Geert R. D'Haens  et al.

RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY
RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY

Geert R. D'Haens  et al.

UNRAVELLING THE ROLE OF THE LYMPHATIC SYSTEM IN THE DEVELOPMENT OF IMMUNOGENICITY TO BIOLOGICS IN INFLAMMATORY BOWEL DISEASE PATIENTS
UNRAVELLING THE ROLE OF THE LYMPHATIC SYSTEM IN THE DEVELOPMENT OF IMMUNOGENICITY TO BIOLOGICS IN INFLAMMATORY BOWEL DISEASE PATIENTS

Geert R. D'Haens  et al.

EFFICACY OUTCOMES BY SYMPTOM-BASED RESPONSE STATUS AFTER INDUCTION: WEEK-48 RESULTS FROM THE GALAXI 1 TRIAL OF GUSELKUMAB IN CROHN’S DISEASE
EFFICACY OUTCOMES BY SYMPTOM-BASED RESPONSE STATUS AFTER INDUCTION: WEEK-48 RESULTS FROM THE GALAXI 1 TRIAL OF GUSELKUMAB IN CROHN’S DISEASE

Geert R. D'Haens  et al.

CLINICAL AND ENDOSCOPIC IMPROVEMENTS WITH RISANKIZUMAB INDUCTION AND MAINTENANCE DOSING VERSUS PLACEBO ARE OBSERVED IRRESPECTIVE OF NUMBER OF PRIOR FAILED BIOLOGICS
CLINICAL AND ENDOSCOPIC IMPROVEMENTS WITH RISANKIZUMAB INDUCTION AND MAINTENANCE DOSING VERSUS PLACEBO ARE OBSERVED IRRESPECTIVE OF NUMBER OF PRIOR FAILED BIOLOGICS

Geert R. D'Haens  et al.

HEAD-TO-HEAD PHARMACOKINETIC ANALYSIS OF INFLIXIMAB MONO- VS COMBINATION THERAPY IN PAEDIATRIC CROHN’S DISEASE
HEAD-TO-HEAD PHARMACOKINETIC ANALYSIS OF INFLIXIMAB MONO- VS COMBINATION THERAPY IN PAEDIATRIC CROHN’S DISEASE

Geert R. D'Haens  et al.

A TRANSCRIPTOME-DEPENDENT PROGNOSTIC MODEL OF RESPONSE IN PATIENTS WITH ULCERATIVE COLITIS
A TRANSCRIPTOME-DEPENDENT PROGNOSTIC MODEL OF RESPONSE IN PATIENTS WITH ULCERATIVE COLITIS

Geert R. D'Haens  et al.

THE EFFECT OF MIRIKIZUMAB ON FECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PHASE 3 STUDIES OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
THE EFFECT OF MIRIKIZUMAB ON FECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PHASE 3 STUDIES OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Geert R. D'Haens  et al.

PERIPHERAL BLOOD DNA METHYLATION PROFILES PREDICT RESPONSE TO USTEKINUMAB AND SHOW STABILITY DURING BOTH INDUCTION AND MAINTENANCE TREATMENT IN CROHN’S DISEASE
PERIPHERAL BLOOD DNA METHYLATION PROFILES PREDICT RESPONSE TO USTEKINUMAB AND SHOW STABILITY DURING BOTH INDUCTION AND MAINTENANCE TREATMENT IN CROHN’S DISEASE

Geert R. D'Haens  et al.

EFFICACY OF UPADACITINIB DOSE ESCALATION IN A PHASE 3 LONG-TERM EXTENSION ULCERATIVE COLITIS STUDY
EFFICACY OF UPADACITINIB DOSE ESCALATION IN A PHASE 3 LONG-TERM EXTENSION ULCERATIVE COLITIS STUDY

Geert R. D'Haens  et al.

EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH MODERATE TO SEVERE ISOLATED PROCTITIS RELATIVE TO THOSE WITH MORE EXTENSIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH MODERATE TO SEVERE ISOLATED PROCTITIS RELATIVE TO THOSE WITH MORE EXTENSIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Geert R. D'Haens  et al.

A SINGLE-CELL RNA SEQUENCING ATLAS OF THE TUMOR ENVIRONMENT IN PERITONEAL METASTASIZED COLORECTAL CANCER IDENTIFIES ANTI-INFLAMMATORY MACROPHAGES AS POTENTIAL TARGETS FOR THERAPY
A SINGLE-CELL RNA SEQUENCING ATLAS OF THE TUMOR ENVIRONMENT IN PERITONEAL METASTASIZED COLORECTAL CANCER IDENTIFIES ANTI-INFLAMMATORY MACROPHAGES AS POTENTIAL TARGETS FOR THERAPY

Geert R. D'Haens  et al.

CHARACTERIZATION OF CYTOKINE AND DRUG CONCENTRATIONS IN SERUM, MUCOSA AND FAECES DURING INDUCTION TREATMENT OF SEVERE ULCERATIVE COLITIS WITH INFLIXIMAB
CHARACTERIZATION OF CYTOKINE AND DRUG CONCENTRATIONS IN SERUM, MUCOSA AND FAECES DURING INDUCTION TREATMENT OF SEVERE ULCERATIVE COLITIS WITH INFLIXIMAB

Geert R. D'Haens  et al.

CONTRAST-ENHANCED ULTRASOUND DISTINGUISHES INFLAMMATORY FROM NON-INFLAMMATORY STENOSIS IN CROHN’S DISEASE: FIRST RESULTS FROM THE STRICTURE STUDY
CONTRAST-ENHANCED ULTRASOUND DISTINGUISHES INFLAMMATORY FROM NON-INFLAMMATORY STENOSIS IN CROHN’S DISEASE: FIRST RESULTS FROM THE STRICTURE STUDY

Geert R. D'Haens  et al.

MUCOSAL B-CELL EXPANSION AND MATURATION CONTRIBUTE TO ULCERATIVE COLITIS PATHOGENESIS
MUCOSAL B-CELL EXPANSION AND MATURATION CONTRIBUTE TO ULCERATIVE COLITIS PATHOGENESIS

Geert R. D'Haens  et al.

Item 41 - 60 / 74
1 2
3
4